My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
November 2017
HIVMA Releases Guideline on HIV and Chronic Pain

New guidelines released by the HIV Medicine Association (HIVMA) and published in Clinical Infectious Diseases recommend that everyone living with HIV be assessed for chronic pain, a significant problem that affects 39 to 85 percent of people living with HIV. These comprehensive guidelines, the first for HIV and chronic pain, provide the tools and resources HIV specialists need to treat these often-complex patients, many of whom struggle with depression, substance use disorders, and have other health conditions.

Those who screen positive should undergo comprehensive evaluation, including a physical exam, psychosocial evaluation, and diagnostic testing. Nearly half of chronic pain experienced by people with HIV is neuropathic, likely due to inflammation or injury to the central or peripheral nervous system caused directly or indirectly by HIV infection. Non-neuropathic pain typically is musculoskeletal, such as low-back pain and osteoarthritis in the joints. These latter problems will be seen more frequently as HIV patients age.

HIV specialists should work with an interdisciplinary team to offer multi-modal treatment. The guidelines recommend offering alternative, non-pharmacological therapies first, including cognitive behavioral therapy, yoga, physical and occupational therapy, hypnosis, and acupuncture. If medication is needed, the guidelines recommend beginning with non-opioids, such as gabapentin and capsaicin, both of which help with neuropathic pain.

The online version of the guidelines includes a list of resources for physicians to reference to help them treat the patients comprehensively.

The guidelines panel included experts who specialize in HIV, substance abuse, pain, psychiatry, palliative care, and pharmacology. In addition to lead authors, Douglas Bruce, MD, MA, MS, and Peter Selwyn, MD, MPH, the guidelines panel included: Ebtesam Ahmed, PharmD; Carla Alexander, MD; Amanda H. Corbett, PharmD; Kathleen Foley, MD; Kate Leonard, MD; Paula J. Lum, MD, MPH; Jessica Merlin, MD, MBA; and Glenn Jordan Treisman, MD, PhD.

Next Article >

Post a comment

Your name:

Your comment:

HIVMA Releases Guideline on HIV and Chronic Pain
ACIP Makes New Recommendations on Shingles, Mumps Vaccines
Weighing in on HHS Report on Vaccine Innovation
Updates on NIHís Next Generation Researchers Initiative
IDSA to UHC: Donít Deny Payment for Cognitive Services
Reimbursement for Telemedicine Could Get Easier
How to Stay Abreast of CMSís Quality Payment Program
IDSA Remains Committed to Fighting Antimicrobial Resistance
FY2018 Funding News
IDSA Continues to Press for Diagnostics Reimbursement
FDA Public Workshop on Antimicrobial Susceptibility Tests
IDSA Member Testifies at New York State Hearing on Lyme Disease
Science Speaks Covers IDWeek, Union World Conference on Lung Health
Congressional Study Tour to CDC Global Health
Fellowship in Stewardship and Resistance Receives CDC Funding
HIVMA Clinical Fellowship and Medical Students Program
PCORI Funding Announcement: Community-Acquired Pneumonia
Maintaining Our Momentum
IDSA Launches Antimicrobial Stewardship Centers of Excellence Program
Updated Guideline on Infectious Diarrhea Now Available
IDWeek 2017 Recap
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.